S100A6 and neoplasm: For example, S100A4 elevation in colorectal cancer has been associated with decreased survival rate [6,38] and S100A4 inhibition using regulators of β-catenin signalling such as niclosamide or sulindac has shown reduction of liver metastasis in mouse xenograft models [39,40]; S100A6 overexpression in gastric cancer could serve as independent prognostic predictor associated with poor survival [41] and S100A6 knockdown in gastric cancer cells has been shown to inhibit tumour growth in vivo [42].